Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other non-small-cell lung cancer (NSCLC) subtypes positive for <em>MET</em> exon 14 skipping alterations (<em>MET</em>ex14-positive).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We did a multicentre, single-arm, open-label, phase 2 study across 32 hospitals in China. Eligible patients were 18 years or older with locally advanced or metastatic <em>MET</em>ex14-positive pulmonary sarcomatoid carcinoma or other NSCLC subtypes, had either presented with disease progression or toxicity intolerance towards one or more standard treatments or were deemed clinically unsuitable for standard treatment, were MET inhibitor-naive, and had measurable disease. Patients received either 600 mg (bodyweight ≥50 kg) or 400 mg (bodyweight <50 kg) of oral savolitinib once daily until disease progression, death, intolerable toxicity, initiation of other anti-tumour therapy, non-compliance, patient withdrawal, or patient discontinuation. Radiographic tumour evaluation was done at baseline, every 6 weeks within 1 year of the first dose, and every 12 weeks thereafter. The primary endpoint was objective response rate, defined as the proportion of patients with confirmed complete or partial responses by independent review committee (IRC) assessment. The primary endpoint was assessed in the tumour response evaluable set, which comprised all treated patients with a measurable lesion at baseline and at least one adequate scheduled post-baseline tumour assessment or the presence of radiological disease progression, with a sensitivity analysis done in the full analysis set, which comprised all patients who received at least one dose of savolitinib. Safety was also evaluated in the full analysis set. This study is registered with <a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>, <a href="https://clinicaltrials.gov/show/NCT02897479">NCT02897479</a>, and recruitment is complete, with treatment and follow-up ongoing.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>From Nov 8, 2016, to Aug 3, 2020, 84 patients with <em>MET</em>ex14 skipping alterations were screened for eligibility, of whom 70 were enrolled, received savolitinib, and comprised the full analysis set. The IRC-assessed tumour response evaluable set comprised 61 patients. At a median follow-up of 17·6 months (IQR 14·2–24·4), the IRC-assessed objective response rate was 49·2% (36·1–62·3; 30 of 61 patients) in the tumour response evaluable set and 42·9% (95% CI 31·1–55·3; 30 of 70 patients) in the full analysis set. All 70 patients reported at least one treatment-related adverse event. Treatment-related adverse events of grade 3 or more occurred in 32 (46%) patients, the most frequent of which were increased aspartate aminotransferase (n=9), increased alanine aminotransferase (n=7), and peripheral oedema (n=6). Treatment-related serious adverse events occurred in 17 (24%) patients, the most common being abnormal hepatic function (n=3) and hypersensitivity (n=2). One death due to tumour lysis syndrome in a patient with pulmonary sarcomatoid carcinoma was assessed to be probably related to savolitinib by the investigator.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>Savolitinib yielded promising activity and had an acceptable safety profile in patients with pulmonary sarcomatoid carcinoma and other NSCLC subtypes positive for <em>MET</em>ex14 skipping alterations. Savolitinib could therefore be a novel treatment option in this population.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>Hutchison MediPharma and AstraZeneca.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Translation</h3><p>For the Chinese translation of the abstract see Supplementary Materials section.</p>

Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report

Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal–epithelial transition exon 14 skipping mutation: a case report and literature review

Circulating Tumour DNA Biomarkers in Savolitinib-Treated Patients with Non-Small Cell Lung Cancer Harbouringmetexon 14 Skipping Alterations: Apost Hocanalysis of a Pivotal Phase 2 Study

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients with NSCLCs Harboring MET Exon 14 Skipping Alterations

The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation

Case Report: Savolitinib Induced Severe Adverse Reactions Resembling Septic Shock in an HIV-1–positive Patient with Advanced Non-Small Cell Lung Cancer

Abstract CT031: Preliminary Efficacy and Safety Results of Savolitinib Treating Patients with Pulmonary Sarcomatoid Carcinoma (PSC) and Other Types of Non-Small Cell Lung Cancer (NSCLC) Harboringmetexon 14 Skipping Mutations

Phase II Study of Savolitinib in Patients (pts) with Pulmonary Sarcomatoid Carcinoma (PSC) and Other Types of Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 Skipping Mutations (Metex14+).

Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: \nSafety, Efficacy, and Biomarkers

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary <i>EGFR</i> L858R mutation and <i>MET</i> amplification: a case report

1MO A Phase IIIb Study of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation

Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract CT158: Ctdna Analysis in the Savolitinib Phase II Study in Non-Small Cell Lung Cancer (NSCLC) Patients (pts) Harboring MET Exon 14 Skipping Alterations (Metex14)